Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01884272 · ClinicalTrials.gov registry record · Phase 1
NSAID Drug Interaction Study
A Phase 1 study of Gout, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01884272: Completed Phase 1 study of Gout, sponsored by Ardea Biosciences.
NCT01884272 is a Phase 1 study of Gout that has completed, run by Ardea Biosciences. The registered enrollment target is 24 participants, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01884272, a Phase 1 study of Gout, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of non-steroidal anti-inflammatory drugs on lesinurad and leinurad on the non-steroidal anti-inflammatory drugs.
Primary Outcome
Profile in terms of AUC, Tmax, Cmax, and t1/2 AUC: area under the plasma concentration versus time curve; Tmax: time to maximum plasma concentration; Cmax: maximum plasma drug concentration; t1/2: apparent terminal half-life
Conditions Studied
Interventions
- DRUG lesinurad 400 mg
- DRUG naproxen 250 mg
- DRUG indomethacin 25 mg
Study Locations (1)
Michigan
- - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
What the finished NCT01884272 record still lists
NCT01884272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 8,888-participant average among 34 other Gout trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 3 interventions - of which lesinurad 400 mg is the first listed.
NCT01884272 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01884272 about?
NCT01884272 is a clinical study titled "NSAID Drug Interaction Study". This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of non-steroidal anti-inflammatory drugs on lesinurad and leinurad on the non-steroidal anti-inflammatory drugs.
What is the current status of trial NCT01884272?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-06. Estimated completion is 2013-10.
What conditions does trial NCT01884272 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT01884272?
The interventions under investigation include: lesinurad 400 mg (DRUG), naproxen 250 mg (DRUG), indomethacin 25 mg (DRUG).
Who is sponsoring clinical trial NCT01884272?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01884272 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01884272's enrollment target sits among peer trials
24 26th of 34 higher than 7 of 34 other Gout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
-
Mild, Moderate and Severe Renal Impairment Study
COMPLETED · Phase 1
-
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
COMPLETED · Phase 1
-
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia